Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability

World Journal of Urology

Volumn 26, Issue 3, 2008, Pages 243-250

  Gunia, Sven ^a   Albrecht, Knut ^b   Koch, Stefan ^a   Herrmann, Thomas ^b   Ecke, Thorsten ^a   Loy, Volker ^a   Linke, Jörg ^a   Siegsmund, Michael ^a   May, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Inter observer variability; Ki67 staining index; Neuroendocrine differentiation; Prognostic outcome; Prostate cancer

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NEUROSECRETORY CELL; OBSERVER VARIATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RETROSPECTIVE STUDY; TIME;

ADULT; AGED; CELL PROLIFERATION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUROENDOCRINE CELLS; OBSERVER VARIATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 44649136679     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0257-0     Document Type: Article

References (29)

1. Green GA, Hanlon AL, Al-Saleem T, Hanks GE (1998) A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer 83:971-976
2. Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S (2006) Percentage of positive biopsy cores, properative prostate specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurence afte radical prostatectomy: A multi-institutional outcome study in Japan. BJU Int 98:549-553
3. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP (2000) Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 56:730-734
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523
5. Epstein JI, Amin M, Bocco- Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R (2005) Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 216:34-63
6. Freedland SJ, Aronson W, Presti JC, Kane CJ, Terris MK, Elashoff D, Amling CL, The SEARCH Database Study Group (2003) Should a positive margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol 169:2142-2146
7. Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS (2003) Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int 92:539-544
8. May M, Kaufmann O, Hammermann F, Loy V, Siegsmund M (2007) Prognostic impact of lymphovascular invasion in radical prostatectomy specimens. BJU Int 99:539-544
9. Li R, Heydon K, Hammond ME, Grignon DJ, Roach M, Wolkov HB, Sandler HM, Shipley WU, Pollack A (2004) Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in radiation theapy oncology group protocol 86-10. Clin Cancer Res 15:4118-41224
10. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM (2004) Ki-67 staining index is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 1992-2002. J Clin Oncol 22:2133-2140
11. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O (2005) Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66:332-337
12. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U (2005) Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 36:562-570
13. Tamas EF, Epstein JI (2006) Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol 30:980-985
14. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN, Evans CP (2007) Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 10:6-14
15. Kinebuchi Y, Noguchi W, Irie K, Nakayama T, Kato H, Nishizawa O (2007) Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostate-specific antigen: A case reprot. Int J Urol 14:147-149
16. Grimaldi F, Valotto C, Barbina G, Visentini D, Trianni A, Cerruto MA, Zattoni F (2006) The possible role of Chromogranin A as a prognostic factor in organ-confined prostate cancer. Int J Biol Markers 21:229-234
17. May M, Siegsmund M, Hammermann F, Loy V, Gunia S (2007) Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 41:375-381
18. Di Sant'Agnese PA, de Mesy Jensen KL (1987) Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 18:849-856
19. Honn KV, Aref A, Chen YQ, Cher ML, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes JE, Powell II, Redman B, Sakr W, Severson R, Tang DG, Wood DP Jr (1996) Prostate cancer-old problems and new approaches. (Part II. Diagnostic and prognostic markers, pathology and biological aspects). Pathol Oncol Res 2:191-211
20. Schiffer E (2004) Biomarkers in prostate cancer. World J Urol 25:557-562
21. Aaltomaa S, Karja V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, Mokka R (2006) Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 26:4873-4878
22. Ojea Calvo A, Mosteiro Cervino MJ, Dominguez Freire F, Alonso Rodigro A, Rodriguez Iglesias B, Benavente Delgado J, Barros Rodriguez JM, Gonzalez Pineiro A (2004) The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progression of the prostate cancer after radical prostatectomy. Actas Urol Esp 28:650-660
23. Hoosein NM (1998) Neuroendocrine and immune mediators in prostate cancer progression. Front Biosci 15:1274-1279
24. Diaz M, Abdul M, Hoosein N (1998) Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate Suppl 8:32-36
25. Chiao JW, Hsieh TC, Xu W, Sklarew RJ, Kancherla R (1999) Development of human prostate cancer cells to neuroendocrine-like cells by interleukin-1. Int J Oncol 15:1033-1037
26. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM (2000) Neutral endo-peptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 106:1399-1407
27. lbrecht M, Doroszewicz J, Gillen S, Gomes I, Wilhelm B, Stief T, Aumüller G (2004) Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1 beta with IL-1 beta acting as a modulator of cellular differentiation. Prostate 58:82-94
28. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A (2007) The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: New therapeutic approaches? World J Urol 25:477-489
29. Potter SR, Epstein JI, Partin AW (2000) Seminal vesicle invasion by prostate cancer: Prognostic significance and therapeutic implications. Rev Urol 2:190-195 Summer